Broadfin Capital’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

Broadfin Capital’s Portfolio SRRA Stock Details SRRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-120,746	Closed	-$8.26M	–	48
2019 Q1	$8.26M	Sell	120,746 -1,262	-1%	-$81K	1.71%	22
2018 Q4	$6.44M	Buy	122,008 +19,749	+19%	+$1.26M	0.85%	30
2018 Q3	$6.95M	Buy	102,259 +49,594	+94%	+$4.5M	1.02%	28
2018 Q2	$6.24M	Buy	+52,665	New	+$5.28M	0.98%	30

Other funds holding SRRA

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Broadfin Capital's SRRA Position: Q2 2019 in Review

Broadfin Capital sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q2 2019, closing a stake of 120,746 shares — an estimated $8.26M sold.

Broadfin Capital first reported a position in SRRA in Q2 2018 and held it in 4 quarters. The position peaked at $8.26M in Q1 2019. 49 funds tracked by Wall St. Rank hold SRRA as of Q2 2019.

Broadfin Capital reported no remaining Sierra Oncology, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
Broadfin Capital sold 120,746 Sierra Oncology, Inc. Common Stock shares in Q2 2019, an estimated $8.26M.
Broadfin Capital first reported a position in Sierra Oncology, Inc. Common Stock in Q2 2018 and held it in 4 quarters.
Broadfin Capital's Sierra Oncology, Inc. Common Stock position peaked at $8.26M in Q1 2019.
49 funds tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q2 2019.

Based on Broadfin Capital's 13F filing for Q2 2019, filed 14 Aug 2019.